Search
Boehringer Ingelheim Forms Strategic Alliance with Re-Vana, Targeting a Deal Worth Over $1 Billion
2025-07-29 /
Read about 0 minute
Author：小编
Boehringer Ingelheim has forged a strategic partnership with Re-Vana Therapeutics to pioneer groundbreaking long-acting sustained-release therapies for ocular diseases. Under this agreement, the two entities intend to launch up to three projects annually, with a potential cumulative deal value surpassing $1 billion. The collaboration aims to harness Re-Vana's advanced long-acting sustained-release injection platform, thereby minimizing the frequency of necessary eye injections and improving patient adherence.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
